ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Acta Pharmacol Sin
; 42(1): 160-170, 2021 Jan.
Article
in En
| MEDLINE
| ID: mdl-32541921
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Coenzyme A Ligases
/
Carcinoma, Hepatocellular
/
Sorafenib
/
Liver Neoplasms
/
Antineoplastic Agents
Type of study:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Animals
/
Humans
/
Male
Language:
En
Journal:
Acta Pharmacol Sin
Journal subject:
FARMACOLOGIA
Year:
2021
Type:
Article
Affiliation country:
China